Auxilium Pharmaceuticals Inc. Sets New 1-Year High at $25.25 (AUXL)
Auxilium Pharmaceuticals (NASDAQ:AUXL) set a new 52-week high during trading hours on Wednesday, AR Network reports. The company traded as high as $25.25 and last traded at $25.19, with a volume of 1,833,164 shares. The stock had previously closed at $23.90.
A number of analysts have recently weighed in on AUXL shares. Analysts at MKM Partners downgraded shares of Auxilium Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Thursday, January 23rd. They now have a $23.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at UBS AG raised their price target on shares of Auxilium Pharmaceuticals from $23.00 to $30.00 in a research note to investors on Friday, January 17th. They now have a “buy” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Auxilium Pharmaceuticals in a research note to investors on Friday, December 20th. They now have a $21.00 price target on the stock. Five research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $23.64.
Auxilium Pharmaceuticals has a 1-year low of $13.87 and a 1-year high of $25.25. The stock’s 50-day moving average is $21.72 and its 200-day moving average is $19.12. The company has a market cap of $1.244 billion and a price-to-earnings ratio of 10.87.
Auxilium Pharmaceuticals (NASDAQ:AUXL) last announced its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.15 by $0.02. The company had revenue of $108.10 million for the quarter, compared to the consensus estimate of $103.66 million. During the same quarter last year, the company posted ($0.21) earnings per share. Auxilium Pharmaceuticals’s revenue was up 52.3% compared to the same quarter last year. Analysts expect that Auxilium Pharmaceuticals will post $0.57 EPS for the current fiscal year.
Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.